Menu Back toAre External Control Arms Ready for Primetime?

DIA 2021 Global Annual Meeting

Are External Control Arms Ready for Primetime?

Session Chair(s)

Zoe  Li, MBA

Zoe Li, MBA

  • Director, Life Sciences
  • COTA, United States
There are increasing examples of companies submitting real-world data as part of an external control arm. This panel will discuss whether external control arms are really ready for regulatory use and what it will take to achieve broader acceptance.
Learning Objective : Describe how and when to use control arms; Discuss the risks and benefits; Identify the FDA's willingness to accept external comparators in regulatory submissions.


Ravinder  Dhawan, PhD


Ravinder Dhawan, PhD

  • Vice President, Outcomes Research, Oncology CORE
  • Merck & Co., Inc., United States
Leah  Burns, MPH


Leah Burns, MPH

  • Group Director, Real World Evidence Strategy
  • Bristol-Myers Squibb Company, United States
Aaron  Kamauu, MD, MPH, MS


Aaron Kamauu, MD, MPH, MS

  • Managing Director
  • Ikaika Health LLC, United States